- Home
- IAUX vs EYPT Comparison
IAUX vs EYPT Comparison
Compare IAUX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IAUX | EYPT |
|---|---|---|
| Founded | 2020 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | IAUX | EYPT |
|---|---|---|
| Price | $1.59 | $14.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.50 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 18.5M | 847.3K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,193,000.00 | $7,539,000.00 |
| Revenue This Year | $132.25 | N/A |
| Revenue Next Year | $89.76 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 89.12 | N/A |
| 52 Week Low | $0.48 | $5.46 |
| 52 Week High | $2.24 | $19.11 |
Technical Indicators
Market Signals| Indicator | IAUX | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 50.68 |
| Support Level | $1.57 | $12.47 |
| Resistance Level | $2.20 | $14.54 |
| Average True Range (ATR) | 0.09 | 0.63 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 35.71 | 61.59 |
Price Performance
Historical ComparisonAbout IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.